Aled Edwards

Aled Edwards is the founding and current CEO of the Structural Genomics Consortium (SGC), a public-private partnership in early drug discovery formed in 2002. He is Professor and Temerty Nexus Chair of Health Innovation and Technology in the Faculty of Medicine at the University of Toronto and is jointly appointed in the Faculty of Law and the Faculty of Applied Science and Engineering. Aled co-founded a number of companies, including YCharOS and M4K Pharma, which were launched based an open science business mode, and Affinium, a drug discovery company. YCharOS was awarded the 2021 Irv and Helga International Prize for Open Science. Affinium, for which he served as founding CEO and then CSO, developed one of only 6 antibiotics in the global pipelines (afabicin) and was sold to Debiopharm, where afabicin continues its clinical development.

Aled is an Ashoka Fellow, an Officer of the Order of Canada, and a Fellow of the Royal Society.